YOLFTbeta
Ocular Therapeutix Inc

Ocular Therapeutix Inc

OCUL · NASDAQ · Healthcare / Biotechnology

6.21USD-0.07 (-1.11%)

Price History

Full chart

Market Stats

Previous Close6.28
Open6.27
Day Range6.00 – 6.38
52-Week Range6.23 – 16.44
Volume2.49M
Market Cap2.12B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.40
Dividend Yield0.00%
Beta0.97
50-Day Avg9.88
200-Day Avg9.85

About

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Pravin U. Dugel M.D.
  • Employees325
  • Headquarters14 Crosby Drive, Bedford, MA, United States, 01730, USA
  • Websitehttps://www.ocutx.com

Leadership

  • Dr. Pravin U. Dugel M.D.Executive Chairman, President & CEO · b. 1964
  • Mr. Donald Notman Jr.Chief Operating Officer (Leave of Absence)
  • Mr. Steve MeyersChief Commercial Officer
  • Mr. Sanjay Nayak MBBS, Ph.D.Chief Strategy Officer · b. 1970
  • Dr. Nadia K. Waheed M.D., M.P.H.Chief Medical Officer · b. 1977
  • Mr. Jason RobinsCFO & Principal Accounting Officer · b. 1977
  • Dr. Peter K. Jarrett Ph.D.Chief Technical Officer · b. 1957
  • Dr. Jeffrey S. Heier M.D.Chief Scientific Officer · b. 1961
  • Mr. William S. Slattery Jr.Vice President of Investor Relations
  • Mr. Todd D.C. Anderman J.D.Chief Legal Officer & Corporate Secretary · b. 1982

Financials

Income Statement

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue10.00K-772.00K1.75M1.89M1.92M1.99M4.23M17.40M43.52M51.49M58.44M63.72M51.82M
Growth (%)---+126.68%+7.83%+1.91%+3.48%+112.41%+311.71%+150.08%+18.32%+13.49%+9.03%-18.67%
Cost of Revenue7.00K10.52M91.00K319.00K443.00K457.00K465.00K2.33M2.08M4.41M4.54M5.28M5.63M6.57M
Gross Profit3.00K-10.52M681.00K1.43M1.44M1.47M1.52M1.90M15.32M39.12M46.95M53.16M58.10M45.25M
Gross Margin30.00%-88.21%81.77%76.52%76.24%76.63%45.00%88.03%89.88%91.18%90.96%91.17%87.31%
Operating Expense13.67M2.39M27.77M39.63M44.77M63.39M60.64M87.70M78.17M117.15M125.61M135.54M229.88M315.27M
Operating Income-13.67M-12.90M-27.09M-38.20M-43.33M-61.92M-59.12M-85.80M-62.85M-78.04M-78.65M-82.38M-171.78M-270.02M
Operating Margin-136710.00%--3509.59%-2182.69%-2296.03%-3220.12%-2970.75%-2029.86%-361.13%-179.30%-152.74%-140.96%-269.57%-521.04%
EBITDA-13.31M-12.50M-26.98M-37.27M-42.14M-59.87M-55.95M-77.74M-146.09M2.54M-61.91M-66.42M-176.14M-249.78M
EBITDA Margin-133120.00%--3495.08%-2129.71%-2233.28%-3113.31%-2811.71%-1839.15%-839.48%5.83%-120.22%-113.64%-276.42%-481.99%
Net Income-14.09M-13.32M-28.65M-39.75M-44.70M-63.39M-57.69M-86.37M-155.64M-6.55M-71.04M-80.74M-193.51M-265.94M
Net Income Margin-140930.00%--3710.88%-2271.31%-2369.00%-3296.20%-2899.10%-2043.34%-894.31%-15.06%-137.95%-138.14%-303.67%-513.17%
R&D11.54M10.52M18.88M26.61M27.07M30.88M36.91M41.09M28.69M50.08M53.46M61.05M127.64M197.10M
R&D as % of Total Revenue115400.00%-2445.60%1520.63%1434.29%1605.82%1855.03%972.11%164.88%115.08%103.82%104.47%200.30%380.33%
Interest Expense377.00K441.00K1.12M1.72M1.68M1.89M1.74M6.10M6.77M6.67M7.02M11.34M13.58M11.84M
Interest Expense % of Total Revenue3770.00%-144.95%98.51%89.03%98.39%87.39%144.33%38.89%15.33%13.64%19.40%21.31%22.84%

Balance Sheet

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets25.29M19.15M78.19M110.31M74.94M55.43M73.04M78.74M261.86M204.89M149.29M252.06M457.94M808.06M
Total Liabilities71.90M78.62M19.50M20.72M22.93M29.28M37.17M82.37M185.77M116.89M113.91M160.93M142.59M153.75M
Total Equity-46.61M-59.47M58.70M89.59M52.01M26.15M35.88M-3.63M76.09M88.00M35.38M91.13M315.34M654.31M
Cash23.85M17.50M37.39M30.78M32.94M41.54M54.06M54.44M228.06M164.16M102.30M195.81M392.10M737.06M
Total Debt4.07M2.46M14.87M15.27M15.64M18.02M24.79M59.34M58.44M58.98M64.28M83.39M75.78M79.78M
Net Debt-19.79M-15.05M-22.53M-15.51M-17.29M-23.52M-29.27M4.91M-169.62M-105.18M-38.02M-112.42M-316.32M-657.28M

Cash Flow

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-12.59M-12.64M-20.50M-33.74M-34.00M-50.47M-49.23M-77.58M-53.55M-65.55M-59.60M-70.23M-134.68M-204.88M
Investing Cash Flow3.81M-387.00K-38.59M-38.57M35.57M27.07M-1.89M-2.24M-841.00K-1.19M-3.71M-6.09M-1.29M-11.88M
Financing Cash Flow27.30M6.68M78.97M65.70M585.00K32.01M68.64M75.34M228.01M2.85M1.45M169.83M332.11M561.72M
Capital Expenditure203.00K387.00K1.26M1.78M1.92M8.25M1.89M2.24M841.00K1.19M3.71M6.09M1.29M12.01M
Free Cash Flow-12.79M-13.03M-21.76M-35.52M-35.92M-58.73M-51.12M-79.82M-54.40M-66.74M-63.32M-76.32M-135.97M-216.89M
Dividends Paid--14.91M2.10M04.38M297.00K37.27M747.00K710.00K-52.57M--
FCF to OCF101.61%103.06%106.15%105.27%105.64%116.35%103.84%102.88%101.57%101.82%106.23%108.67%100.96%105.86%
Dividend Paid to FCF---68.54%-5.92%0.00%-7.47%-0.58%-46.70%-1.37%-1.06%--68.88%--

Earnings

Report DateAug 29, 2014Nov 12, 2014Mar 10, 2015May 15, 2015Aug 10, 2015Nov 10, 2015Mar 10, 2016May 10, 2016Aug 9, 2016Nov 9, 2016Mar 10, 2017May 5, 2017Aug 8, 2017Nov 7, 2017Mar 8, 2018May 8, 2018Aug 7, 2018Nov 7, 2018Mar 7, 2019May 10, 2019Aug 7, 2019Nov 12, 2019Mar 12, 2020May 8, 2020Aug 7, 2020Nov 5, 2020Mar 11, 2021May 5, 2021Aug 9, 2021Nov 8, 2021Feb 28, 2022May 9, 2022Aug 8, 2022Nov 7, 2022Mar 6, 2023May 8, 2023Aug 7, 2023Nov 7, 2023Mar 11, 2024May 7, 2024Aug 7, 2024Nov 14, 2024Mar 10, 2025May 5, 2025Aug 5, 2025Nov 4, 2025Feb 5, 2026May 5, 2026Aug 3, 2026Nov 3, 2026
EPS Estimate--0.32-0.38-0.39-0.33-0.38-0.47-0.43-0.49-0.50-0.45-0.48-0.57-0.53-0.52-0.41-0.37-0.37-0.38-0.42-0.48-0.46-0.45-0.49-0.32-0.25-0.17-0.21-0.21-0.26-0.23-0.22-0.18-0.21-0.25-0.24-0.29-0.25-0.30-0.18-0.21-0.21-0.22-0.28-0.35-0.35-0.34-0.31-0.40-0.36
EPS Actual-2.10-0.44-0.37-0.35-0.45-0.47-0.43-0.43-0.46-0.39-0.52-0.58-0.64-0.54-0.44-0.40-0.37-0.38-0.42-0.48-0.57-0.45-0.53-0.41-0.64-0.19-1.21-0.29-0.29-0.28-0.05-0.25-0.21-0.30-0.24-0.31-0.26-0.19-0.35-0.24-0.26-0.22-0.29-0.37-0.39-0.38-0.29-0.40-0.35-
Surprise--37.50%2.63%10.26%-36.36%-23.68%8.51%0.00%6.12%22.00%-15.56%-20.83%-12.28%-1.89%15.38%2.44%0.00%-2.70%-10.53%-14.29%-18.75%2.17%-17.78%16.33%-100.00%24.00%-611.76%-38.10%-38.10%-7.69%78.26%-13.64%-16.67%-42.86%4.00%-29.17%10.34%24.00%-16.67%-33.33%-23.81%-4.76%-31.82%-32.14%-11.43%-8.57%14.71%-29.03%12.50%-
Timing-Pre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap2.12B
Enterprise Value1.68B
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales40.71
Price / Book4.22
EPS-1.40
Book Value2.37
Revenue (TTM)52.05M
Gross Profit (TTM)-178.16M
EBITDA-308.46M
Profit Margin0.00%
Operating Margin-609.34%
Return on Equity-72.99%
Return on Assets-34.95%
Shares Outstanding219.62M
Shares Float184.76M
Beta0.97
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 12 analystsTarget 27.09
  • Strong Buy
    6
  • Buy
    6

Ownership Breakdown

Institutions
95.70%
Insiders
0.93%
Retail / Other
3.37%

Top Institutional Holders

  • FMR Inc
    32.65M14.87%
  • Deep Track Capital, LP
    19.69M8.96%
  • BlackRock Inc
    16.13M7.35%
  • venBio Select Advisor LLC
    12.31M5.61%
  • SUMMER ROAD LLC
    12.21M5.56%
  • VR Adviser, LLC
    10.35M4.71%
  • Vanguard Capital Management, LLC
    8.72M3.97%
  • T. Rowe Price Associates, Inc.
    5.90M2.69%
  • Point72 Asset Management, L.P.
    5.53M2.52%
  • Logos Global Management LP
    5.30M2.41%
  • State Street Corp
    4.71M2.14%
  • Geode Capital Management, LLC
    4.53M2.06%
  • AllianceBernstein L.P.
    4.13M1.88%
  • Dimensional Fund Advisors, Inc.
    2.78M1.27%
  • Balyasny Asset Management LLC
    2.69M1.23%

Top Fund Holders

  • Fidelity Growth Company Fund
    9.70M4.42%
  • Vanguard MStar Total Stk Mkt Idx Invest
    6.64M3.02%
  • iShares Russell 2000 ETF
    5.21M2.37%
  • Fidelity Growth Company K6
    2.70M1.23%
  • Fidelity Series Growth Company
    2.61M1.19%